Study of Immunity Dysfunction Induced by Extracorporeal Assistance (ECMO / ECLS)
Completed
- Conditions
- Acute Respiratory Distress SyndromeCardiogenic Shock
- Interventions
- Biological: Blood test
- Registration Number
- NCT03262155
- Lead Sponsor
- Rennes University Hospital
- Brief Summary
Study of immunosuppression biomarkers in patients with ARDS or cardiogenic shock with ECMO / ECLS, compared to patients with ARDS or cardiogenic shock without ECMO / ECLS
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 18
Inclusion Criteria
- Patient older than 18 years old
- Patient hospitalized in an intensive care unit
- Patient whose initial ARDS or Cardiogenic shock began less than 5 days before admission
- Patients hospitalized for ARDS or Cardiogenic shock with ECMO / ECLS or - Patients hospitalized for ARDS or Cardiogenic shock without ECMO / ECLS
Exclusion Criteria
- Opposition of patient, relative or legal representative for participation in the study
- Pregnant woman
- Pre-immunodepression
- Implementation of immunosuppressive therapy such as chemotherapy, cyclophosphamide, high-dose corticosteroids (> 0.5mg / kg / day).
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description No ECMO / ECLS Blood test Patients hospitalized for ARDS or Cardiogenic shock without ECMO / ECLS ECMO / ECLS Blood test Patients hospitalized for ARDS or Cardiogenic shock with ECMO / ECLS
- Primary Outcome Measures
Name Time Method Prevalence of immunosuppression in patients with ARDS or cardiogenic shock under ECMO / ECLS hospitalized in intensive care unit Hour 24
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
CHU de Rennes
🇫🇷Rennes, France